The Alcobra Ltd. (ADHD) Stock Rating Lowered by Roth Capital

The Alcobra Ltd. (ADHD) Stock Rating Lowered by Roth Capital

Alcobra Ltd. (NASDAQ:ADHD) was downgraded by Roth Capital from a “buy” rating to a “neutral” rating in a report issued on Tuesday.

Several other equities research analysts also recently weighed in on ADHD. Cantor Fitzgerald set a $2.00 price target on Alcobra and gave the stock a “hold” rating in a research report on Tuesday. Stifel Nicolaus set a $2.00 price target on Alcobra and gave the stock a “hold” rating in a research report on Tuesday. Jefferies Group downgraded Alcobra from a “buy” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research lowered shares of Alcobra from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, Piper Jaffray Companies set a $2.00 target price on shares of Alcobra and gave the stock a “hold” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $4.68.

Shares of Alcobra (NASDAQ:ADHD) opened at 1.03 on Tuesday. The stock has a 50 day moving average price of $2.05 and a 200 day moving average price of $3.26. The company’s market capitalization is $28.39 million. Alcobra has a one year low of $0.83 and a one year high of $5.75.

Alcobra (NASDAQ:ADHD) last announced its quarterly earnings results on Tuesday, November 15th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02. The business earned $7.90 million during the quarter, compared to the consensus estimate of $4.30 million. On average, equities research analysts predict that Alcobra will post ($0.94) earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of ADHD. Credit Suisse AG raised its position in shares of Alcobra by 39.5% in the third quarter. Credit Suisse AG now owns 83,795 shares of the company’s stock worth $207,000 after buying an additional 23,717 shares in the last quarter. Knoll Capital Management LP bought a new position in shares of Alcobra during the third quarter worth $2,799,000. Baker BROS. Advisors LP bought a new position in shares of Alcobra during the third quarter worth $5,771,000. VHCP Management II LLC raised its position in shares of Alcobra by 5.7% in the third quarter. VHCP Management II LLC now owns 1,537,463 shares of the company’s stock worth $3,798,000 after buying an additional 83,061 shares in the last quarter. Finally, VHCP Management LLC raised its position in shares of Alcobra by 5.7% in the third quarter. VHCP Management LLC now owns 658,910 shares of the company’s stock worth $1,628,000 after buying an additional 35,597 shares in the last quarter. 63.15% of the stock is currently owned by hedge funds and other institutional investors.

About Alcobra

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Related posts

Leave a Comment